Blog

Affirm Holdings, Inc. AFRM reported fiscal third-quarter 2025 earnings of a penny against the Zacks Consensus Estimate of a loss of nine cents per share and the prior-year quarter’s loss of 43 cents

OUTFRONT Media Inc. OUT reported first-quarter 2025 adjusted funds from operations (AFFO) per share of 14 cents, missing the Zacks Consensus Estimate of 15 cents. The reported figure remained

Dollar Tree, Inc. DLTR is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 15.85, which is lower than the industry’s average of 32.52 and the broader Zacks Retail-Wholesale

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth

• (1:00) - Should You Be Investing Into High Paying Income Stocks?
• (8:40) - Top Stocks To Keep On Your Watchlist Right Now
• (36:45) - Episode Roundup: WHR, PFE, CVX, CC, DOW
•                 Podcast@Z

Insmed INSM reported a first-quarter 2025 loss of $1.42 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.36. In the year-ago quarter, the company posted a loss of $1.06

Theravance Biopharma TBPH reported first-quarter 2025 adjusted net loss of 17 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 11 cents. In the year-ago quarter, the

BILL Holdings BILL reported earnings of 50 cents per share in the third quarter of fiscal 2025, beating the Zacks Consensus Estimate by 35.14%. However, the reported figure decreased 16.7% year over

RingCentral RNG reported that in the first quarter of 2025, non-GAAP earnings were $1 per share, surpassing the Zacks Consensus Estimate by 4.17% and increasing 14.9% year over year.Total revenues

B2Gold Corp BTG reported adjusted earnings per share (EPS) of 9 cents for first-quarter 2025, beating the Zacks Consensus Estimate of 8 cents. The bottom line improved 50% year over year.Including

Anheuser-Busch InBev SA/NV BUD, aka AB InBev, reported first-quarter 2025 results. The company’s earnings per share (EPS) beat the Zacks Consensus Estimate and improved year over year. However, the

Shares of Key Tronic Corporation KTCC have lost 6.6% since reporting results for the third quarter of fiscal 2025. This compares to the S&P 500 index’s 0.1% decline over the same time frame. Over

Wolverine World Wide, Inc. WWW reported impressive first-quarter 2025 results, wherein the top and bottom lines surpassed the Zacks Consensus Estimate. Also, revenues and earnings grew year over

Alliant Energy Corporation LNT reported first-quarter 2025 operating earnings of 83 cents per share, which beat the Zacks Consensus Estimate of 57 cents by 45.6%. The bottom line also rose 33.9%

Intellia Therapeutics NTLA incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks

Microchip Technology MCHP reported fourth-quarter fiscal 2025 non-GAAP earnings of 11 cents per share, which beat the Zacks Consensus Estimate by 28.57% and plunged 81.5% year over year.Net sales of

Limbach (LMB) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its

United Bankshares (UBSI) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue

Rigel Pharmaceuticals (RIGL) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might

Investors might want to bet on CorMedix (CRMD), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and

Investors might want to bet on Astronics Corporation (ATRO), as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price